S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

ROIV Roivant Sciences Ltd

12.00

0.03 (0.25%)

Last Updated: 11:50:17

Delayed by 15 minutes

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Article too big to display. Click here to view on the SEC website

Roivant Sciences (NASDAQ:ROIV)
Historical Stock Chart
From Nov 2024 to Dec 2024

Click Here for more Roivant Sciences Charts.

Roivant Sciences (NASDAQ:ROIV)
Historical Stock Chart
From Dec 2023 to Dec 2024

Click Here for more Roivant Sciences Charts.

Roivant Sciences Ltd News

Kinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis
Tuesday 3 December 2024 (3 weeks ago) • GlobeNewswire Inc.

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update
Tuesday 12 November 2024 (1 month ago) • GlobeNewswire Inc.

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024
Tuesday 29 October 2024 (2 months ago) • GlobeNewswire Inc.

Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
Monday 28 October 2024 (2 months ago) • GlobeNewswire Inc.

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
Wednesday 18 September 2024 (3 months ago) • GlobeNewswire Inc.

Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress
Tuesday 10 September 2024 (3 months ago) • GlobeNewswire Inc.

Roivant Provides Update on Graves’ Disease Development Program
Monday 9 September 2024 (3 months ago) • GlobeNewswire Inc.

Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update
Thursday 8 August 2024 (5 months ago) • GlobeNewswire Inc.

Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024
Thursday 25 July 2024 (5 months ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 30 May 2024 (7 months ago) • Edgar (US Regulatory)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Thursday 30 May 2024 (7 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 30 May 2024 (7 months ago) • Edgar (US Regulatory)

More Roivant Sciences Ltd News Articles

Hallmark Venture (PK)

Virexit Technologies (PK)

Intergrated Cannabis Sol... (PK)

ELine Entertainment (CE)

Asia Broadband (PK)

Anavex Life Sciences

SMC Entertainment (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions